![Bernd Kastler](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Bernd Kastler
Directeur Général chez Kastler GmbH
Postes actifs de Bernd Kastler
Sociétés | Poste | Début | Fin |
---|---|---|---|
Kastler GmbH
![]() Kastler GmbH Financial ConglomeratesFinance Kastler GmbH is an investment holding German company. The CEO of the private company is Bernd Kastler. | Directeur Général | - | - |
Directeur/Membre du Conseil | - | 11/06/2015 |
Historique de carrière de Bernd Kastler
Anciens postes connus de Bernd Kastler
Sociétés | Poste | Début | Fin |
---|---|---|---|
elbion AG
![]() elbion AG Miscellaneous Commercial ServicesCommercial Services elbion AG discovers and develops new small molecule drugs for the treatment of inflammatory and central nervous system diseases with high unmet medical need. It's lead product candidate AWD 12-281 is a topical inhibitor and is in phase IIa trials for the treatment of chronic obstructive pulmonary disease and has licensed it to GlaxoSmithKline for exclusive development and commercialization. It focuses on target areas, including PDE inhibitors and CNS modulators, in terms of novel chemistries, novel assays and mechanisms of action, as well as in-house animal disease models. Founded in 2002, the company is headquartered in Radebeul, Germany. | President | - | - |
BIOTIE THERAPIES CORP | Directeur/Membre du Conseil | 01/06/2009 | - |
Independent Dir/Board Member | 14/11/2008 | - |
Formation de Bernd Kastler
University of Giessen | Doctorate Degree |
Statistiques
Internationale
Allemagne | 4 |
Finlande | 2 |
Opérationnelle
Director/Board Member | 2 |
Independent Dir/Board Member | 1 |
President | 1 |
Sectorielle
Health Technology | 2 |
Commercial Services | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 3 |
---|---|
Biotie Therapies Oy
![]() Biotie Therapies Oy Pharmaceuticals: MajorHealth Technology Biotie Therapies Oy engages in the research, development, and commercialization of pharmaceutical products. The company was founded by Markku Tapani Jalkanen and Sirpa Tuulikki Jalkanen in June 1992 and is headquartered in Helsinki, Finland. | Health Technology |
elbion AG
![]() elbion AG Miscellaneous Commercial ServicesCommercial Services elbion AG discovers and develops new small molecule drugs for the treatment of inflammatory and central nervous system diseases with high unmet medical need. It's lead product candidate AWD 12-281 is a topical inhibitor and is in phase IIa trials for the treatment of chronic obstructive pulmonary disease and has licensed it to GlaxoSmithKline for exclusive development and commercialization. It focuses on target areas, including PDE inhibitors and CNS modulators, in terms of novel chemistries, novel assays and mechanisms of action, as well as in-house animal disease models. Founded in 2002, the company is headquartered in Radebeul, Germany. | Commercial Services |
Kastler GmbH
![]() Kastler GmbH Financial ConglomeratesFinance Kastler GmbH is an investment holding German company. The CEO of the private company is Bernd Kastler. | Finance |
- Bourse
- Insiders
- Bernd Kastler
- Expérience